Alvotech

Welcome to the second quarter earnings call for Alvatech. To ask a question during the session, you will need to press star 1 and 1 on your telephone. You will then hear an automated message advising your hand is raised. Please be advised that today's conference is being recorded. I would now like to introduce and hand over the call to Benedict Stephenson, Director of Investor Relations and Global Communications of Alvatech. Please proceed.

Thank you, and good morning or afternoon to everyone joining this call today. Yesterday evening, the company issued a press release that can be found on our website, www.albutex.com. The release outlines key highlights related to our second quarter results. Additionally, presentation slides that cover our call today will be posted on our website at www.albutex.com. Our presentation materials and some of our statements that we make today may include forward-looking statements. These statements do not ensure future performance and are subject to risks and uncertainties that are outlined in company filings with the Securities and Exchange Commission and the NASDAQ Iceland Stock Exchange. These risks and uncertainties could cause actual results to differ materially from forward-looking statements that are made. With me on today's call are Robert Westman, Executive Chairman and Founder of Avotech, who will give you a quick overview and recap recent strategic milestones. Mark Levick, Chief Executive Officer will cover our portfolio and competitive landscape. Anil Oke, Chief Commercial Officer, who will give a commercial update. Joel Morales, Chief Financial Officer, who will review the financial highlights. And finally, Ming Li, Chief Strategic Officer, who will present our newly published ESG portal and ESG disclosures for 2020 to 2021. With that, I would like to turn the call over to Robert Westman, who is Executive Chairman and founder of Alvotech.

Robert Westman Thank you, Benedek. I want to welcome everyone to our second quarter earnings call. This is actually our first active call for Alva Tech as a public company. We believe that biosimilar stands to benefit in long term as the healthcare systems are struggling with cost. Biosimilars have the potential to help make healthcare more sustainable. On the June 16th, we made our debut at Nasdaq in New York. And on June 23rd, we listed on NASDAQ First North Market in Reykjavik, Iceland. Alvatech is the only company who are listed in both Europe and Iceland, and one of the few to play by similar companies with scale that are publicly traded. Alvatech is a company that has taken 10 years and over a billion dollars to build. We have been fortunate to make these investments and built our company meanwhile being private. We are very proud of being and having very strong R&D, a manufacturing platform, and having pipeline of eight biosimilars and biosimilar candidates with an addressable market over $85 billion. We employ over 800 people around the world with more than 85% focus on R&D, technical operational quality. Our state-of-the-art facility in Reykjavik is designed to support the growth of our pipeline through 2030, handling end-to-end manufacturing of drug substance, drug product, as well as fill and finish. We have established global reach across six continents and well over 90 countries with a network of 15 high-quality regional partners that are experts in their home markets. In addition to allowing us to leverage our partners' expertise and commercial infrastructure, we are entitled to substantial milestones and approximately 40% of in-market sales. Of course, the backbone of the company is our leadership team. Although by a very young industry, they have also been quite blessed to recruit experienced and accomplished leaders. with relevant experience to join us. This includes our CEO, Mark Levick, who previously led Biosimilars at Sandow, and Joe McClellan, our Chief Scientific Officer, who led Biosimilars development at Pfizer. Most of our senior executives have had direct experience with Biosimilars, and we believe that historical knowledge has helped us to navigate AlvoTech to where we are today. Before I pass the presentation over to our CEO, Mark, I want to highlight the main changes in the business that have taken place since we announced our business combination with O3 Acquisition Core 2. Since then, we have had substantial advancement across our portfolio, including IP clearance around our lead product, AVTO2, a high concentration bias similar to Humira, as well as FDA acceptance of our BLA that included supporting data to gain interchangability for the U.S. market. We have also launched the product in multiple markets. But beyond that, it is important in biosimilars to be multi-product, and we have advanced our biosimilar candidates for Stellera, ILEA, Proglia, and Xgeva. In case of Stellera, we have reported positive top one result, making us only the second company to do so. On the corporate side, we have, of course, listed in both the U.S. and Iceland, and we have recently announced plans to move our Icelandic listing from First North Market to the main port, which we believe can open up more opportunities for Alvotax. We have also expanded our board of directors to increase both diversity and independence. Finally, we have made available an ESG portal which provides further transparency to our sustainability efforts and performance metrics. We look forward to continue to update our stakeholders and shareholders on our progress as we continue to execute on our strategy that focus on biosimilars and the promise to bring these valuable medicines to patients around the world. With that, I would like to turn the presentation over to Mark Levick, our Chief Executive Officer. Over to you, Mark.